

**Renal and Ureteric Stones Guideline Committee**  
**Declarations of Interest**

**Andrew Dickinson, Consultant Urologist**

	Declaration	Classification	Action
Application/interview	None	-	-
GC01	<p>Chair of British Association of Urological Surgeons (BAUS) Education committee 2015-2017:            Committee involved in all aspects of urological education for medical (undergraduate and postgraduate) and allied health care professionals.</p> <p>Vice chair Surgical Speciality Board for Royal College of Surgeons of Edinburgh (2015-2018)            This committee provides advice on all aspects of urology to the Council of the Royal College. I do not have a specific role for advice on Renal and ureteric stones</p> <p>Plymouth Urology Private Practice LLP based at Plymouth Nuffield Hospital:            Management of private patient with urological diagnoses. Practice reflects NHS practice except vasectomy reversal (not available on NHS). No specific interest of treatment of renal and ureteric stones from April 2017.</p>	<p>Non-specific personal non-financial</p> <p>Non-specific personal non-financial</p> <p>specific personal financial</p>	<p>Declare and participate</p> <p>Declare and participate</p> <p>Declare and participate</p>
GC02	None	-	-
GC 03	None	-	-
GC04	<p>Delegate at BAUS Section of Endourology annual meeting Leeds September 2017. Funded by Plymouth Hospital NHS Trust (PHNT) study leave budget and self-funding. Received 9 CME points for attendance as part of annual CME requirements</p> <p>Co-author on poster abstract accepted at EAU Section of Urolithiasis EULIS stone meeting Vienna October 2017. Title: Metabolic joint stone clinic: setting up a new service;</p>	<p>Non-specific Non-personal financial</p> <p>Non-specific personal non-financial</p>	<p>Declare and participate</p> <p>Declare and participate</p>

	Authors: T Dutton, M Moore, A Dickinson, A Connor.		
GC05	None		
GC06&07	None		

**Alan Chant, Lay member**

	Declaration	Classification	Action
Application/interview	None	-	-
GC01	None	-	-
GC02	None	-	-
GC03	None	-	-
GC04	Sent apologies		
GC05	None		
GC06&07	None		

**Chris Sills, Lay member**

	Declaration	Classification	Action
Application/interview		-	-
GC01	Sent apologies	-	-
GC02	Sent apologies	-	-
GC03	None	-	-
GC04	Sent apologies		
GC05	Sent apologies		
GC06&07	Sent apologies		

**Dave Maudgil, Consultant Radiologist**

	Declaration	Classification	Action
Application/Interview	private practice includes reporting scans for the following organisations: BMI healthcare, Spire Healthcare, Bridge Clinic Advanced Imaging and Radiology Reporting Online	specific personal financial	tbc
GC01	None	-	-
GC02	None	-	-
GC03	Sent apologies	-	-
GC04	Elected to the Communications Committee of the British Society of Interventional Radiology	Non-specific personal non-financial	Declare and participate
GC05	None		

GC06&07	None		
---------	------	--	--

**Jane Collie, Urology Nurse Practitioner**

	Declaration	Classification	Action
Application/Interview	Involved in recruitment of patients to the NIHR studies SUSPEND, TISU and PURE.  I am involved in the development of PROMS (patient reported outcome measures) in Cambridge for both ureteric stones and renal stones, and have had presentations on the projects at national and international meetings, as well as abstracts published in journals.	Specific Non-Personal Financial  Non-Specific Personal Non-financial	Declare and participate
GC01	None	-	-
GC02	None	-	-
GC03	Abstract submitted to World Congress of Endourology – Nov 2017. 'Emergency Extracorporeal Shockwave Lithotripsy (ESWL) for acute ureteric colic: Outcomes from a large UK tertiary centre'.	Specific personal non-financial	Declare and participate
GC04	None		
GC05	None		
GC06&07	None		

**Kathryn Griffith, Principal in General practice**

	Declaration	Classification	Action
Application/interview	None	-	-
GC01	None	-	-
GC02	None	-	-
GC03	None	-	-
GC04	None		
GC05	None		
GC06&07	None		

**Kay Thomas, Consultant Urological Surgeon**

	Declaration	Classification	Action
--	-------------	----------------	--------

Application/interview	Local principal investigator – TISU trial current (lithotripsy) non-personal financial Recruited patients for NIHR study -TISU	Specific non-personal financial	-declare and participate
GC01	Co-chair Cystinuria Rare Disease Register Group (RaDaR)	Non-Specific personal non-financial	Declare action at discretion of Chair
GC02	None	-	-
GC03	None	-	-
GC04	Lecture given on prevention of renal stones to the Royal Society of Medicine Oct 2017. Usual expenses for attendance  Author of abstracts presented at World Congress of Endourology Canada 2017. Did not personally attend . Are patient information days useful for patients with Cystinuria? A patients' perspective  Protein modelling- A novel approach to risk stratify disease in patients with cystinuria  What Doses Are Our Patients Receiving? An audit examining the radiation dose associated with CT KUB, CT IVU and intra operative fluoroscopy during ureteroscopy and PCNL.	Specific personal financial  Non-specific personal non-financial	Declare and participate  Declare and participate
GC05	Abstract marking for European Urology Annual meeting-rare diseases section  Attended panel meeting on update of European Guideline Urolithiasis	Non-specific personal financial  Specific personal non-financial	Declare and participate  Declare and participate
GC06&07	None		

**Nick Leggett, Lay member**

	Declaration	Classification	Action
Application/interview	None	-	-
GC01	None	-	-
GC02	None	-	-

GC03	None	-	-
GC04	None		
GC05	None		
GC06&07	None		

**Robert Calvert, Consultant Urological Surgeon**

	Declaration	Classification	Action
Application/Interview	<p>Support by company EDAP TMS to attend the European Association of Urology Annual Meeting in London in March 2017). Registration fees and usual expenses paid by commercial company to employer for attendance. Gave educational talk on lithotripsy machines for which no payment received.</p> <p>Private Practice at Spire Liverpool Hospital Director of Liverpool Urology Ltd. Urological treatments including stone management</p>	<p>Specific non -personal Financial</p> <p>specific personal financial</p>	<p>Declare and participate</p> <p>Declare and participate</p>
GC01	None	-	-
GC02	None	-	-
GC03	<p>Course director for BAUS Residential Operative Endourology, Oct 2017. Industry sponsorship from Strong and Boston to subsidize delegate fees (not received directly).</p> <p>Invited speaker Chilean Urological Congress, Nov 2017. They are providing transport and accommodation</p> <p>Invited speaker RSM, Oct 2017. They are providing travel.</p> <p>Invited speaker BAUS Endourology Annual Meeting, Sept 2017. Accommodation paid.</p>	<p>Specific non-personal financial</p> <p>Specific personal financial</p> <p>Specific personal financial</p> <p>Specific -personal financial</p>	<p>Declare and participate</p> <p>Declare and participate</p> <p>Declare and participate</p> <p>Declare and participate</p>
GC04			
GC05	Abstract reviewer for European Urology annual meeting 2018. Kidney stones: medical research	Specific personal non-financial	Declare and participate

GC06&07	Invited speaker at Chilean Urological Society Annual Meeting held in November 2017. No payment received. Only travel and accommodation expenses covered.	Specific Personal financial	Declare and participate
---------	--	-----------------------------	-------------------------

**Sally Ann Hulton, Consultant Paediatric Nephrologist**

	Declaration	Classification	Action
Application/Interview	Consultation for scientific advice for research trial in Primary Hyperoxaluria paid by Alnylam Pharmaceuticals. Rare renal stone condition - September 2014.  PI for current mRNAi trial for Primary Hyperoxaluria.in children Alnylam and Dicerna pharma. Recruiting for trial	Non-Specific Personal financial  Non-Specific Non-personal Financial	Declare and participate
GC01	Chair of Primary Hyperoxaluria UK Rare Disease group (RADAR)	non- Specific personal non-financial	Declare: and participate
GC02	None	-	-
GC03	Consultancy scientific advice to Dicerna Pharmaceutical regarding development of new SRNAi medication for primary hyperoxaluria. Consultancy fee paid directly to Renal Research Fund a Birmingham Children's Hospital. No personal financial gain.	non-Specific non-personal financial	Declare and participate
GC 04	President-Elect British Association for Paediatric Nephrology (BAPN). Presidency starts June 2018.	Specific personal non-financial	Declare and participate Standing down from Committee from February 2018.
GC05	Sent apologies		
GC06&07	None		

**Shabbir Moochhala, Consultant Nephrologist**

	Declaration	Classification	Action
Application/Interview	Principal investigator for a commercially-funded but investigator-led interventional trial to treat primary hyperoxaluria (Alnylam). Not due to complete during development of guideline.	Non-Specific Non-personal Financial	Declare and participate

GC01	Chair for the Rare Disease group (RADAR) for Adenine phosphoribosyltransferase deficiency (APRTd) hosted by the Renal Association	Non Specific personal non-financial	Declare action at discretion of Chair
GC02	None	-	-
GC03	Apologies sent	-	-
GC04	Chair of the Rare Disease Group Hyperoxaluria within the National Registry of Rare Kidney Diseases (RADAR) from Sept 2017	Non-specific personal non-financial	Declare and participate
GC05	Speaker at EULIS (section of Urolithiasis, European Association of Urology conference 6.10.17 on calcium pathophysiology	Non-specific personal non-financial	Declare and participate
GC06&07	None		

**Soha Zouwail, Consultant Chemical pathologist**

	Declaration	Classification	Action
Application/interview	None	-	-
GC01	None	-	-
GC02	None	-	-
GC03	Apologies sent	-	-
GC04	None		
GC05	None		
GC06&07	None		

**Stephen Griffin, Consultant Paediatric Urologist**

	Declaration	Classification	Action
Application/interview	Treasurer of the Journal of Paediatric Urology company	Non-Specific Personal Non-Financial	Declare and participate
	Associate editor (Paediatric Urology) British Journal of Urology International Knowledge	Non-Specific Personal Financial	
	Central reader of urodynamics for Pfizer study (A0221047) – a phase 3 trial assessing the efficacy of fesoterodine for treatment of neurogenic detrusor over-activity in children	Non-Specific Non-personal Financial	

GC01	E-tutor for joint RCS Edinburgh/ university of Edinburgh in urology	Non-specific personal Non-financial	Declare and participate
GC02	None	-	-
GC03	None	-	-
GC04	None		
GC05	None		
GC06&07	Speaker at RSM. 'Challenges in paediatric urology and nephrology' and 'Urinary tract illness in Children' scheduled for 23 02 2018.' Travel expenses only.	Specific Personal financial	Declare and participate

**Co-optee: Susan Kennedy, Clinical Lead Renal Dietician**

	Declaration	Classification	Action
Application/interview	None	-	-
GC01	None	-	-
GC02	None	-	-
GC03	N/A	-	-
GC04	N/A		
GC05	N/A		
GC06&07	None (Only attended GC06)		